LABP

Landos Biopharma, Inc. Common Stock
LABP

Delisted

LABP was delisted on the 23rd of May, 2024.

Back to rankings

16 hedge funds and large institutions have $34.9M invested in Landos Biopharma, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.

Upgrade to unlock
New
Increased
Maintained
Reduced
Closed

more first-time investments, than exits

New positions opened: | Existing positions closed:

more capital invested

Capital invested by funds: $ → $

more funds holding

Funds holding: →

Holders
16
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$332K
2
+$96.4K
3
+$69K
4
PCM
PenderFund Capital Management
British Columbia, Canada
+$61.7K
5
Renaissance Technologies
Renaissance Technologies
New York
+$50.6K

Top Sellers

1
-$154
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$31.9M
DAM
2
Deltec Asset Management
New York
$1.07M
Renaissance Technologies
3
Renaissance Technologies
New York
$406K
Macquarie Group
4
Macquarie Group
Australia
$316K
VF
5
Virtu Financial
New York
$313K
Geode Capital Management
6
Geode Capital Management
Massachusetts
$271K
PCM
7
PenderFund Capital Management
British Columbia, Canada
$271K
BMCM
8
Black Maple Capital Management
Wisconsin
$223K
UBS Group
9
UBS Group
Switzerland
$87.7K
TRCT
10
Tower Research Capital (TRC)
New York
$19.2K
Acadian Asset Management
11
Acadian Asset Management
Massachusetts
$2K
JP Morgan Chase
12
JP Morgan Chase
New York
$1.27K
Royal Bank of Canada
13
Royal Bank of Canada
Ontario, Canada
$1K
Morgan Stanley
14
Morgan Stanley
New York
$279
CPG
15
Cornerstone Planning Group
New Jersey
$267
Wells Fargo
16
Wells Fargo
California
$215
BlackRock
17
BlackRock
New York
–